IDgenix (AdvanceAD Tx)
Moderate-to-Severe Atopic Dermatitis
Commercial/Early LaunchActive
Key Facts
Indication
Moderate-to-Severe Atopic Dermatitis
Phase
Commercial/Early Launch
Status
Active
Company
About Castle Biosciences
Castle Biosciences is a mission-driven company focused on transforming disease management by applying precision genomics to high-stakes clinical decisions. Since its 2008 founding, it has built a commercially successful portfolio of proprietary tests, supported by over 150 peer-reviewed publications and more than 300,000 test reports delivered. Its strategy centers on addressing critical unmet needs in dermatologic, ocular, and gastrointestinal oncology through its multi-analyte GEP platform, driving growth via clinical validation, payer coverage, and market penetration.
View full company profileTherapeutic Areas
Other Moderate-to-Severe Atopic Dermatitis Drugs
| Drug | Company | Phase |
|---|---|---|
| Lebrikizumab | Eli Lilly | Regulatory Review |
| Amlitelimab | Sanofi | Phase 3 |
| Zumilokibart (APG777) | Apogee Therapeutics | Phase 2 |
| APG279 (Zumilokibart + APG990) | Apogee Therapeutics | Phase 1 |
| Ebglyss/Lebrikizumab | Almirall | Marketed/Registration |
| Rademikibart (CBP-201) | Connect Biopharma | Phase 3 |